Can this Peninsula startup make a cancer-fighting drug with lackluster results work?

The company recently raised $130 million to help it build its portfolio of cancer-fighting drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.